2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4971 RNA-binding proteins recruited to the replication fork represent novel dependencies in acute myeloid leukemia

Xiaoqin Zhu, MD, MS, Jacob Kurek, B.s.2, Sean Walulik3, Crystal Potter, B.a.4, Mark Wunderlich, Manager5, Kenneth Greis6, Taylor Lange7, Sydney Yearout8, Megan Bones9, Linde A Miles, PhD10, Susanne Wells, PhD11, Nicolas Nassar, PhD12, Andrew Volk, PhD13
1 University of Cincinnati, Cincinnati, Ohio, United States
2 University of Cincinnati, Cincinnati, Ohio, United States
3 University of Cincinnati, Cincinnati, Ohio, United States
4 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
6 University of Cincinnati, Cincinnati, Ohio, United States
7 University of Cincinnati, Cincinnati, Ohio, United States
8 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
9 University of Cincinnati, Cincinnati, Ohio, United States
10 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
11 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
12 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
13 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States

Background: Acute Myeloid Leukemia (AML) has a low overall survival rate and is characterized by myeloid differentiation blockage leading to expansion of immature self-renewing blasts. Exhausting AML by differentiation is a promising therapeutic strategy. Replication-associated factors are potential targets as cell fate choices are enforced during S phase when chromatin is assembled on newly replicated DNA. Epigenetic control of cell fate during replication is mediated by the Chromatin Assembly Factor 1 (CAF-1) complex through its canonical nucleosome assembly role. Perturbation of CAF-1 by knockdown/knockout of core subunits leads to differentiation and loss of leukemogenicity in AML models, but total loss of CAF-1 is unacceptably toxic to healthy cells. Since CAF-1 lacks catalytic domains, we hypothesized we could disrupt its pro-leukemic function by targeting CAF-1 scaffolding partners. In doing so, we discovered a previously unknown mechanism where AML cells enforce genomic and transcriptional fidelity associated with the immature state by utilizing CAF-1 to scaffold RNA-binding proteins on chromatin. 

Methods: We used a panel of AML cell lines for proteomics approaches to find candidates that (1) localize to CAF-1 using APEX2-CHAF1B proximity biotinylation, (2) co-immunoprecipitate on chromatin with CHAF1B by RIME, and (3) enrich at the replication fork by iPOND. We prioritized hits against a published CRISPR screen to stratify for drivers of differentiation, used shRNA/Cas9-sgRNA to generate loss of function, and genetic complementation rescue assays to assess leukemic state. Finally, we used long-read Oxford Nanopore Sequencing, FLAIR and IsoQuant to explore alternative splicing changes following HNRNPL loss in AML models and healthy CD34 peripheral blood stem cells (PBSCs). 

Results: AML cells enlist RNA-binding proteins as replication-associated factors to maintain transcriptional and genomic integrity associated with leukemic state. HNRNPL emerged as our top CAF-1-associated hit following orthogonal prioritization. HNRNPL, a canonical mRNA splicing factor, is co-expressed with CAF-1 core subunits CHAF1A and CHAF1B, and its perturbation scores tightly correlate with CAF-1 in AML. HNRNPL depletion phenocopies CAF-1 disruption with loss of clonogenicity and cell death due to differentiation in AML models in vitro and profound loss of leukemic potential of PDX models engrafted in NSGS recipients in vivo. While complete knockout of HNRNPL is lethal to healthy cells, partial depletion induces differentiation and loss of leukemic capacity in AML cells with no discernable effect in healthy human CD34 peripheral blood stem cells (PBSCs), suggesting an exploitable therapeutic window of sensitivity unique to leukemic cells. We found HNRNPL loss leads to accumulation of DNA damage over multiple replications, so in conjunction with its localization to sites of active replication, we expected HNRNPL to be a transcription/replication conflict (TRC) resolution factor. However, TRCs were not increased following HNRNPL depletion, indicating DNA damage was unlikely to arise from defective conflict resolution. Given HNRNPL's canonical role in mRNA processing, we tested whether disruption of alternative splicing underlies the selective loss of leukemic fitness. Using long-read sequencing to assess alternative splicing following HNRNPL depletion effects in a panel of AML cell lines and CD34 PBSCs, we found extensive transcriptomic remodeling in AML models. Skipped exon events represented the predominant class of dysregulated splicing events while isoform-level analyses highlighting substantial heterogeneity in full-length transcript architecture in key AML oncogenes including NPM1, MYB, and IDH1/2. Importantly, HNRNPL selectively maintains splicing fidelity of RNA metabolism, cell cycle, and DNA damage response pathways in leukemic models compared to healthy PBSCs. These defects connect HNRNPL loss to DNA damage accumulation and provide a mechanistic basis for the selective vulnerability of AML cells relative to normal hematopoietic progenitors. 

Conclusions: Increased demand to support leukemic capacity means AML cells must enlist existing factors for new or expanded roles. Our work demonstrates that the CAF-1/HNRNPL axis maintains replicative and transcriptomic integrity required for leukemic cell-state maintenance. This is a novel AML dependency and therapeutic intervention opportunity to selectively target the leukemic state. 

Xiaoqin Zhu, MD, MS: No relevant conflicts of interest to declare.